Clearmind Medicine Inc.

Clearmind Medicine Inc. is a clinical-stage pharmaceutical company focused on developing novel psychedelic medicines for widespread, underserved health problems, specifically mental health disorders such as Alcohol Use Disorder (AUD), binge drinking, eating disorders, depression, anxiety, and cocaine addiction. The company's core business model revolves around the research, development, and eventual commercialization of proprietary neuroplastogen-based therapies, with a primary focus on its lead compound, MEAI (5-methoxy-2-aminoindane). Revenue generation is currently not from product sales, as the company is in the clinical development stage, and profitability is dependent on successful completion of development, regulatory approvals, and subsequent manufacturing, marketing, and commercialization. The company aims to address significant unmet medical needs and believes its treatments could reduce the substantial economic burden associated with these disorders, citing an estimated $477.5 billion ¹ in annual avoidable costs related to mental health inequities in the U.S., projected to reach $1.26 trillion ² by 2040.

The company's detailed product and service line breakdown centers on MEAI, a proprietary, non-hallucinogenic neuroplastogen molecule. MEAI is being developed for the treatment of AUD, weight loss and metabolic disorders, and as an alcohol substitute in consumer products. Pre-clinical studies have been completed in the U.S. and China, including pharmacokinetic and toxicological studies in rats and dogs, and metabolism studies. An animal model of AUD demonstrated MEAI's ability to curb alcohol cravings at doses of 40 mg/kg/day ³ and above in mice. The company also conducted research on 2-fluorodeschloroketamine (2-FDCK) for depression and treatment-resistant depression (TRD), and on 5-MAPB and 6-APB as potential fail-safes for MDMA therapy, though there are no immediate plans for further investigation into these latter two compounds.

For the reported fiscal period ended October 31, 2025, Clearmind Medicine Inc. incurred operating losses of $5,667,177 ⁴, with an accumulated deficit of $27,879,724 ⁵. The company has never generated any revenue from product sales. Net losses for the years ended October 31, 2025, 2024, and 2023 were $3,856,983 ⁶, $5,254,678 ⁷, and $8,620,837 ⁸, respectively. Cash flows from operations were negative $4,734,498 ⁹ as of October 31, 2025. The company's cash and cash equivalents stood at $3,923,058 ¹⁰ as of October 31, 2025.

Year-over-year comparisons show a decrease in operating losses from $6,303,434 ¹¹ in 2023 to $5,667,177 ¹² in 2025, and a decrease in net losses from $8,620,837 ¹³ in 2023 to $3,856,983 ¹⁴ in 2025. The company's financial position indicates it is still in the early stages of development, with no revenue generation and continued reliance on equity financing.

Significant operational developments during the period include the initiation of a first-in-human Phase I/IIa clinical trial with CMND-100 for AUD. The company received approval from the Israeli Ministry of Health in February 2024 ¹⁵ and FDA 'Safe to Proceed' clearance in July 2024 ¹⁶ to initiate this trial. The CM-CMND-001 clinical trial was initiated in May 2023 ¹⁷ in both Israel and the United States, with IRB approvals received from Johns Hopkins University in October 2024 ¹⁸, Yale University in December 2024 ¹⁹, Tel Aviv Sourasky Medical Center (TASMC) in August 2025 ²⁰, and Hadassah Medical Center in August 2025 ²¹. Site initiation at TASMC was announced in July 2025 ²², and at Hadassah Medical Center in November 2025 ²³. In November 2025 ²⁴, the Data and Safety Monitoring Board (DSMB) unanimously approved the continuation of the Phase I/IIa clinical trial for CMND-100 following a positive interim safety review, noting no serious adverse events, general good tolerability, and strong treatment observance. The DSMB recommended increasing the CMND-100 treatment concentration to 40mg ²⁵. The company also entered into a clinical supply agreement with IMP Clinical Supply Services in May 2023 ²⁶ for the global clinical supply chain of CMND-100. Furthermore, the company has expanded its intellectual property portfolio, which now consists of nineteen utility patent families, including thirty-two granted patents and eighty pending applications ²⁷. This includes new patent families for compositions comprising MEAI and n-acylethanolamines and uses thereof, MEAI for the treatment of cocaine addiction, MEAI for the treatment of metabolic syndrome, and various other psychedelic compounds in combination with n-acylethanolamines for different mental disorders, as well as MEAI for the treatment of depression and eating disorders. The company also entered into license agreements with Yissum Research Development Company of the Hebrew University of Jerusalem and BIRAD, the research and development company of Bar-Ilan University, for joint patents and exclusive licenses related to metabolic syndrome, anti-obesity, cocaine addiction, PTSD, and other mental disorders.

Management's specific guidance for the upcoming period is not explicitly stated in the filing. The company notes that it does not anticipate generating revenue from product sales for at least the next several years.

The primary growth area for Clearmind Medicine Inc. is the continued clinical development and eventual commercialization of MEAI for the treatment of Alcohol Use Disorder (AUD) and obesity and metabolic disorder. The company is currently conducting a multinational, multi-center, double-blind, Phase I/IIa clinical trial (CM-CMND-001) for CMND-100 (MEAI) in healthy volunteers and AUD subjects. The Phase I part is an open-label, randomized study evaluating the safety and pharmacokinetics of single ascending doses of MEAI oral capsules in up to 4 cohorts with 6 subjects per dose ²⁸. The Phase IIa part is a double-blind, randomized, placebo-controlled study assessing the safety of multiple doses of MEAI in healthy volunteers and AUD subjects, with a secondary endpoint of evaluating the potential effect on drinking patterns and cravings. Two cohorts of 18 subjects ²⁹ per cohort will receive the highest tolerated doses and placebo (2:1 ratio) ³⁰ for five consecutive days ³¹. The company intends to seek regulatory approval through the FDA's 505(b)(1) regulatory path, which requires extensive research to demonstrate safety and efficacy. Upon successful completion of the Phase I/IIa studies, additional clinical trials will be required, subject to securing additional financing. The company also aims to develop an alcohol substitute consumer product based on MEAI.

Another significant growth vector is the development of MEAI for weight loss, obesity, and metabolic syndrome. Pre-clinical studies at Hebrew University demonstrated that MEAI at 40 mg/kg ³² significantly reduced overweight and adiposity in obese mice, normalized hyperglycemia, glucose intolerance, and hyperinsulinemia, and positively impacted liver steatosis and hepatic lipid accumulation. A combination treatment of MEAI and Palmitoylethanolamide (PEA) was also examined, showing increased oxygen consumption, carbon dioxide emission, energy expenditure, and fat oxidation, particularly at 20 and 10 mg/kg ³³ of MEAI, along with a striking reduction in food consumption at 40 and 20 mg/kg ³⁴. These results warrant further preclinical testing.

The operational outlook includes an expectation of increased expenses and operating losses for the foreseeable future as the company continues clinical development of MEAI for AUD and obesity and metabolic disorder, advances preclinical and R&D programs, seeks regulatory and marketing approvals, and potentially establishes sales, marketing, and distribution infrastructure. The company also expects to incur additional ongoing costs associated with operating as a public company. Manufacturing of cGMP material for future clinical trials or potential commercial sales is also a factor. The company relies on third-party manufacturers and CROs for clinical trials and manufacturing, and any disruptions or failures in these relationships could lead to delays and increased costs.

Planned capital allocation will be directed towards funding ongoing preclinical and anticipated clinical trials of MEAI, the cost, timing, and outcomes of regulatory review, and the development of other product candidates. The company also expects to incur costs for preparing, filing, and prosecuting patent applications, maintaining and enforcing intellectual property rights, and defending intellectual property-related claims. As of October 31, 2025, the company had cash and cash equivalents of $3,923,058 ³⁵, and will require significant additional financing to fund its operations. The company may seek additional capital if market conditions are favorable or for specific strategic considerations.

Structural headwinds and execution risks explicitly flagged by management include the inherent uncertainty and high risk of failure in clinical and preclinical development, the lengthy and expensive marketing approval process, and the potential for delays in receiving necessary approvals for MEAI or future products. The company's product candidates contain psychedelic substances, which may be subject to controlled substance laws and regulations, and their use may generate public controversy, potentially leading to delays in approval or increased expenses. There is also a risk that interim or preliminary clinical trial data may change, and that manufacturing problems could cause delays. The company may not be able to take advantage of expedited development or regulatory review processes. Furthermore, the company has no sales, distribution, or marketing experience and will need to establish these capabilities or enter into third-party agreements. The third-party payor coverage and reimbursement status of newly approved products is uncertain, and unfavorable pricing regulations or policies could harm the business.

Geographic, regulatory, or macro factors identified as constraints include the potential for MEAI to be classified as a Schedule I controlled substance in the U.S., which would prevent it from being prescribed, marketed, or sold. In Canada, Health Canada has stated MEAI is a controlled substance due to its similarity to amphetamines, and in Israel, the Ministry of Health considers 2-Aminoindane derivatives, including MEAI, as controlled substances. The company conducts clinical trials outside the U.S., and there is no assurance that the FDA or other regulatory authorities will accept data from such trials. International expansion exposes the company to risks such as conflicting laws, foreign exchange fluctuations, political and economic instability, and limited intellectual property protection in some countries. The ongoing security situation in Israel, including the war with Hamas and hostilities with other organizations, could affect operations, although the company has not experienced disruptions to its clinical studies, facilities, or supply chain as of the filing date. However, renewed or expanded conflict could cause harm.

The company faces material risks including substantial doubt about its ability to continue as a going concern, having incurred operating losses of $5,667,177 ³⁶ for the year ended October 31, 2025, and an accumulated deficit of $27,879,724 ³⁷. There is significant financial risk due to never having generated revenue from product sales and the need to raise substantial additional funding, which may not be available on acceptable terms, or at all. Clinical development of product candidates, particularly those containing psychedelic substances like MEAI, is inherently uncertain, lengthy, and expensive, with high failure rates and potential for delays in regulatory approvals from bodies such as the FDA and EMA. Regulatory hurdles include the potential for MEAI to be scheduled as a Schedule I controlled substance in the U.S., preventing commercialization, and the evolving and restrictive controlled substance laws in various jurisdictions, including Canada and Israel. Public controversy surrounding psychedelic substances could also negatively impact market acceptance. Operational risks include reliance on third parties for clinical trials and manufacturing, which may lead to insufficient quantities of product candidates or delays, and the lack of internal sales, distribution, and marketing experience. Intellectual property protection is crucial but uncertain, with risks of patent challenges, insufficient patent lifespan, and difficulties in enforcing rights globally. Macroeconomic factors such as unfavorable economic and market conditions, inflation, and geopolitical instability, including the security situation in Israel, could adversely affect business operations, financial condition, and the ability to secure financing. Compliance with complex and evolving healthcare, data protection (e.g., GDPR, CCPA, CPRA), and environmental, health, and safety laws also poses significant risks, with potential for substantial penalties and reputational harm for non-compliance.

Management's message to shareholders conveys a tone of determined pursuit of novel therapeutic solutions for significant unmet mental health needs, particularly Alcohol Use Disorder (AUD), obesity, and metabolic disorders, leveraging neuroplastogen-based therapies. They emphasize the belief that their lead compound, MEAI, a non-hallucinogenic molecule, holds the potential to address these widespread health problems and contribute to a "revolution in medicine." Management highlights the progress in clinical development, specifically the initiation of the Phase I/IIa clinical trial for CMND-100 in AUD patients, and the positive interim safety review by the DSMB in November 2025 ³⁸, which unanimously approved the continuation of the trial and recommended increasing the CMND-100 treatment concentration to 40mg ³⁹. Despite acknowledging the company has incurred losses since inception and has not generated product sales revenue, management's strategic priorities for the period ahead are clearly focused on successfully completing the development of MEAI and any future product candidates, obtaining necessary regulatory approvals, and establishing the infrastructure for manufacturing, marketing, and commercialization. They also stress the importance of expanding their intellectual property portfolio and exploring additional applications for MEAI, such as for cocaine addiction and metabolic syndrome, often in collaboration with academic institutions.